NEW UZBEKISTAN: THE EFFECTIVENESS OF ARTIFICIAL INTELLIGENCE-BASED DIGITAL TRANSFORMATION BY 2030
Science and Innovation · 2026
DOI: 10.67620/sai.57a0006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science and Innovation, 2026. Verfasst von S Gulyamov und 1 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
This article examines the effectiveness of Uzbekistan’s artificial-intelligence (AI)-based digital transformation within the “New Uzbekistan” development paradigm. Drawing on official statistics and international rankings for 2020–2025, the study analyses changes in the E-Government Development Index (EGDI), growth in ICT service exports, the condition of digital infrastructure, and the country’s AI-readiness indicators. The findings indicate substantial progress, including a rise to 63rd place in the 2024 EGDI, IT Park exports approaching USD 1 billion, and Uzbekistan’s leading position in Central Asia in the Oxford Insights Government AI Readiness Index. However, the analysis also identifies persistent constraints, including an interregional digital divide, shortages of specialised skills, and the digital sector’s still limited contribution to GDP. Three development scenarios to 2030 are proposed. Under the optimistic scenario, effective implementation of the national AI strategy could contribute an additional 2–3% to GDP growth.
Zitieren
APA
Gulyamov, S., & Mukhitdinova, K. (2026). NEW UZBEKISTAN: THE EFFECTIVENESS OF ARTIFICIAL INTELLIGENCE-BASED DIGITAL TRANSFORMATION BY 2030. Science and Innovation. https://doi.org/10.67620/sai.57a0006
Vancouver
Gulyamov S, Mukhitdinova K. NEW UZBEKISTAN: THE EFFECTIVENESS OF ARTIFICIAL INTELLIGENCE-BASED DIGITAL TRANSFORMATION BY 2030. Science and Innovation. 2026. doi:10.67620/sai.57a0006
BibTeX
@article{Gulyamov2026,
author = {Gulyamov, S and Mukhitdinova, Kh},
title = {NEW UZBEKISTAN: THE EFFECTIVENESS OF ARTIFICIAL INTELLIGENCE-BASED DIGITAL TRANSFORMATION BY 2030},
journal = {Science and Innovation},
year = {2026},
doi = {10.67620/sai.57a0006}
}
EUVIMED